Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

NCT02189772 | Completed Phase 2

• 1 other identifier: AL015
• Study Type: interventional
• Target: 83
• Locations: 1 country
• Sites: 6

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of a single administration of Metadoxine Extended Release (MDX) formulation for the treatment of adolescents diagnosed with ADHD that have predominantly inattentive symptoms. The study will also try to evaluate the efficacy of MDX and its level in the blood.

Conditions

ADHD, Predominantly Inattentive Type

Keywords

ADHD; Inattention; MDX

Outcome Measures

Primary Outcomes (1)

• Safety and Tolerability

  Frequency of treatment emergent adverse events (AEs). Frequency of subjects who withdrew early from the study due to AE.

  Up to 6 weeks

Secondary Outcomes (2)

• Efficacy

  Up to 5 weeks

• PK

  Up to 5 weeks

Other Outcomes (1)

• Exploratory endpoint

  Up to 5 weeks

Study Arms (2)

MDX (metadoxine extended release)

EXPERIMENTAL

Route of administration: oral The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows: * 40-49 kg 700 mg consisting of a 700 mg tablet * 50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet * 65-100 kg 1400 mg consisting of two 700 mg tablets

Drug: Metadoxine extended release

placebo

PLACEBO COMPARATOR

Placebo tablets will be similar in appearance (color and size) to the investigational product

Drug: Placebo

Interventions

Metadoxine extended release DRUG

MG01CI

Also known as: MDX

MDX (metadoxine extended release)

Placebo DRUG

Inactive drug

Also known as: Sugar pill

placebo

Eligibility Criteria

• Age: 13 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Adolescent males and females, 13-17 years old, inclusive, at screening visit, with visible axillary hair.
• Diagnosed with predominantly inattentive ADHD based on DSM V criteria for ADHD as assessed by the Adolescent ADHD Clinician Diagnostic Scale (Adol-CDS V1.2).
• Clinical severity of at least a moderate level (Clinical Global Impression-Severity score of 4 or above).
• STAI State score of \<52, STAI Trait score of \<52 and BDI score of \<19.
• Sexually active subjects of childbearing potential must agree to use an effective contraceptive throughout the study (e.g., oral contraceptives or Norplant®; a reliable double barrier method of birth control \[diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam\]; intrauterine devices; vasectomy; or abstinence) and for at least a month after the study, and must have a negative serum pregnancy test at the Screening Visit. Females of childbearing potential are defined as women who are between menarche and 2 years post-menopause and who are not surgically sterilized. Males and Female subjects who are not sexually active, and who agree to be abstinent throughout the study, will not be required to use birth control.
• Subject is able to attend the clinic regularly and reliably.
• Subject is able to swallow tablets and capsules.
• Able to understand, read, write and speak Hebrew fluently to complete study related materials.
• Parents or legal authorized guardians (LAR), and subject, able to understand and sign written informed consent/assent to participate in the study
• Subject and parents/LARs provide assent/consent to participate in the study. per applicable laws and regulations
• Subject weighs ≥40 kg or ≤100 kg

You may not qualify if:

• Subject has any psychiatric condition (e.g., schizophrenia or personality disorder as diagnosed by DSM-V) or clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation as determined by the investigator using medical history, physical examination, neurological examination, laboratory tests, and electrocardiograms. Common diseases such as mild hypertension, well-controlled type 2 diabetes mellitus (hemoglobin A1C \<6.5%), etc, are allowed per the investigator's judgment as long as they are stable and controlled by medical therapy that is constant for at least 8 weeks before randomization and subsequently throughout the study. If there are any concerns about the suitability of the subject's medical or surgical condition, the investigator should review the subject's history with the medical monitor.
• Subject has a known or suspected human immune deficiency virus positive status or has diseases such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.
• Subject has a history of an allergy or sensitivity to B-complex vitamins.
• Subject has a history of intellectual disability or a history or suspicion of autism spectrum disorder.
• Subject has a current clinically significant Axis I diagnosis (other than ADHD) according to the K-SADS-PL or has a lifetime history of bipolar disorder or psychosis.
• Subject has used mega-dose vitamin B6/pyridoxine during the 28 days before the Randomization Visit. Subjects will be allowed to have a 28-day washout of mega-dose vitamin B6/pyridoxine after the Screening visit. Routine multivitamin supplements will be allowed.
• Subject has used high-dose supplements of omega-3 fatty acids ≥ 500 mg on at least 1 day (such as softgels, capsules, or fish oils; regular daily dietary consumption of fish is allowed) or folic acid supplements (other than routine multivitamin supplements) during the 2 weeks before the Randomization Visit.
• Subject has used an investigational medication/treatment in the 30 days before the Screening Visit
• Subject has used any medication or food supplement that the investigator or the medical monitor considers unacceptable during the 14-day period before randomization. This includes, but is not limited to, sympathomimetic agents, clonidine, guanfacine, norepinephrine reuptake inhibitors, serotonin reuptake inhibitors, sedative-hypnotics, benzodiazepines, sedating antihistamines, herbal preparations that would confound safety or efficacy assessments, and narcotics. Questions regarding the acceptability of medications and food supplements (such as melatonin) will be discussed with the medical monitor before study entry.
• Subject has a current drug or alcohol dependence or substance abuse disorder according to DSM-V Text Revision criteria (excluding nicotine) or a history of such dependence within the last 6 months. Subject should also agree to keep their caffeine intake consistent and refrain from consuming ≥300 mg per day of caffeine (no more than three 8-ounce servings of coffee) during the study.
• Subject has suicidality, defined as active ideation, an intent or plan, or any significant lifetime suicidal behavior (actual attempt, aborted attempt, interrupted attempt, or act or preparation towards imminently making a suicide attempt). Subjects exhibiting history (within previous 12 months) of non-suicidal self-injurious behavior will be excluded.
• Subject has taken any prescription or non-prescription ADHD medications during the 14 days before the randomization visit or 28 days in the case of atomoxetine..
• Subject is significantly visually impaired to an extent that is not able to be corrected by prescription glasses or contact lenses
• Subject is closely related to the sponsor, investigator, or study staff. Eligibility of subjects with any relationship to the sponsor, investigator, or study staff will be discussed with the medical monitor before study entry.
• Subject has any condition that, in the principal investigator's opinion, would place the subject at risk or influence the conduct of the study or interpretation of results, including (but not limited to) abnormally low intellectual capacity as judged by the investigator.

Sponsors & Collaborators

• Alcobra Ltd.: lead

Study Sites (6)

Rambam Medical Center

Haifa, Israel, Israel

Location

Hadassah-Hebrew University Medical Center,

Jerusalem, Israel, Israel

Location

Geha Medical Centre

Petah Tikva, Israel, Israel

Location

The Chaim Sheba medical center, Tel Hashomer

Ramat Gan, Israel, Israel

Location

Assaf Harofeh MC

Zrifin, Israel, Israel

Location

Shalvata Mental Health Center

Hod HaSharon, Israel

Location

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Interventions

Sugars

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Carbohydrates

Study Officials

• Iris Manor, MD

  ADHD Unit, Geha Medical Center, Petah Tikva, Israel

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 11, 2014
• First Posted: July 15, 2014
• Study Start: August 1, 2014
• Primary Completion: January 1, 2015
• Study Completion: January 1, 2015
• Last Updated: March 4, 2015

Record last verified: 2014-12

Locations

IL (6)